A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Phase of Trial: Phase III
Latest Information Update: 13 Jul 2018
At a glance
- Drugs Ulobetasol (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Bausch Health Companies; Valeant Pharmaceuticals International
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 26 Apr 2017 Status changed from recruiting to completed.
- 24 May 2016 Status changed from not yet recruiting to recruiting.